<p>Ch1: Laboratory Assessment of Lipoproteins in Diabetes</p><p>David R. Sullivan</p><p>Barry Lewis</p><p> </p><p>Ch2: Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin Resistance Diabetes</p><p>Michael Cobble</p><p>Patrick D. Mize</p><p>Eliot A. Brinton</p><p> </p><p>Ch3: Insulin Resistance and Atherosclerosis</p><p>Kamalpreet Singh</p><p>Vasudevan A. Raghavan</p><p> </p><p>Ch4: Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes</p><p>Thomas D. Dayspring</p><p> </p><p>Ch5: Lipoprotein Metabolism and Alterations induced by insulin resistance and diabetes</p><p>Gerald H. Tomkin</p><p>Daphne Owens </p><p> </p><p>Ch6: Production and Metabolism of Triglyceride-Rich Lipoproteins in both the Normal and Diabetic States </p><p>Angela Pirillo</p><p>Giuseppe D. Norata</p><p>Alberico L. Catapano</p><p> </p><p>Ch7: Lipoprotein(a): Structure, Metabolism and Pathophysiology</p><p>Alicia J. Jenkins</p><p>Karam M. Kostner</p><p>Gerhard M. Kostner</p><p> </p><p>Ch8: Lipoprotein Glycation in Diabetes Mellitus</p><p>Alicia J. Jenkins</p><p>Richard L. Klein</p><p>Andrzej S. Januszewski</p><p></p><p><br/>Ch9: Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus</p><p>Marielle Kaplan</p><p>Michael Aviram</p><p>Tony Hayek</p><p> </p><p>Ch10: The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes</p><p>Maria F. Lopes-Virella</p><p>Gabriel Virella</p><p> </p><p>Ch11: Lipid – Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes</p><p>Narin Osman</p><p>Peter J.</p> Little<p></p><p> </p><p>Ch12: Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus</p><p>Richard L. Klein</p><p> </p><p>Ch13: Endothelial Dysfunction and Dyslipidaemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy</p><p>Sandra J. Hamilton</p><p>Gerald F. Watts</p><p> </p><p>Ch14: Lipoproteins and Diabetic Nephropathy</p><p>Ville-Petteri Mäkinen</p><p>Nina Tolonen</p><p>Per-Henrik Groop</p><p> </p><p>Ch15: Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy</p><p>Mingyuan Wu</p><p>Timothy J. Lyons</p><p> </p><p>Ch16: Effects of Lifestyle (Diet, Plant Sterols, Excercise) and Glycemic Control on Lipoporteins in Diabetes </p><p>Peter Clifton</p><p> </p><p>Ch17: About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus</p><p>Anthony Keech</p><p>Alicia J. Jenkins</p><p>Val Gebski</p><p> </p><p>Ch18: Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients</p><p>Seth S. Martin</p><p>Parag H. Joshi</p><p>Steven R. Jones</p><p> </p><p>Ch19: The PPAR System in Diabetes</p><p>Jean Claude Ansquer</p><p>Christelle Foucher</p><p> </p><p>Ch20: Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients</p><p>Eliot A. Brinton</p><p> </p><p>Ch21: Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients</p><p>Henry A. Tran</p><p>Arthur Z. Schwartzbard</p><p>James A. Underberg</p><p> </p><p>Ch22: Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus</p><p>Harold Bays</p><p> </p><p>Ch23: Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes </p><p>Peter J. Little</p><p>Alan Chait</p><p>Andrzej S. Januszewski</p><p>Alex Bobik</p><p>David O’Neal</p><p>Alicia J. Jenkins</p>
